Abstract

Delayed and impaired bone fracture healing are associated with diabetic populations. This is a challenging problem for orthopaedic surgeons especially in the US where the percentage of type 2 diabetic patients continues to climb at an alarming rate. Limited treatment options exist for orthopaedic surgeons to improve fracture healing, and the most commonly used therapies involve placement of proteins (bone morphogenetic protein), graft tissue, or demineralized bone matrix at the fracture site. We have previously demonstrated that local administration of the main megakaryocyte growth factor, thrombopoietin, enhances bone healing. Here we demonstrate the utility of systemically administering thrombopoietin mimetic peptides (TMPs) to improve impaired fracture healing in a mouse model of type 2 diabetes. Briefly, 120 male mice on a C57BL/6 background were placed on a low fat diet (LFD) or high fat diet (HFD) for 12 weeks prior to undergoing a surgically created femoral fracture. Mice were treated with 33 nmol/kg of TMP or saline immediately after surgery and daily for the following week. Mice were euthanized at 1, 2, and 4 weeks post-surgery (n=10/group). Here, we confirmed that HFD resulted in impaired fracture healing. We also showed accelerated bone union and increased callus formation in TMP treated mice compared to saline groups, irrespective of diet (p<0.05). Among TMP groups that were fed either a HFD or LFD, the HFD TMP group showed greater improvements in bone healing compared to the HFD saline control mice. Further study on TMP should include alternative routes of administration and providing treatment when a surgical repair appears to be deteriorating. Although there is more to be understood about the clinical importance and mechanism by which systemic TMP treatment enhances fracture healing, these data appear promising.

Highlights

  • Departments of 1Orthopaedic Surgery and 2Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN; 3Novosteo Inc., West Lafayette, IN; Departments of 4Chemistry and 5Medicinal Chemistry and Pharmacology, Purdue University, West Lafayette, IN; Department of 6Biology, Indiana University Purdue University, Indianapolis, Indianapolis, IN; 7Richard L

  • Delayed and impaired bone fracture healing are associated with diabetic populations. This is a challenging problem for orthopaedic surgeons especially in the US where the percentage of type 2 diabetic patients continues to climb at an alarming rate

  • We have previously demonstrated that local administration of the main megakaryocyte growth factor, thrombopoietin, enhances bone healing

Read more

Summary

Introduction

Samuel Zike1, Jeffery Nielsen3,4,5, Caio de Andrade Staut1, Vincent Alentado2, Ushashi Dadwal1, Christopher Dalloul1, Abduallah Elsayed1, Nicholas Hux1, Nikhil Tewari1, Mustafah Shaikh1, Sarah Myers1, Murad Nazzal1, Hanisha Battina1, Rachel Blosser1, Jiliang Li6, Stewart Low3,5, Mary Niedrauer3, Philip Low4,5, Melissa Kacena1,7 Departments of 1Orthopaedic Surgery and 2Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN; 3Novosteo Inc., West Lafayette, IN; Departments of 4Chemistry and 5Medicinal Chemistry and Pharmacology, Purdue University, West Lafayette, IN; Department of 6Biology, Indiana University Purdue University, Indianapolis, Indianapolis, IN; 7Richard L. Delayed and impaired bone fracture healing are associated with diabetic populations.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call